계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Neurophth Therapeutics
company
About
Neurophth is China's first gene therapy company for ophthalmic diseases.
- 251 - 500
Details
- Last Funding Type
- Angel
- Industries
- Biotechnology,Life Science
- Founded date
- Jul 1, 2016
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
¥130M
Neurophth Therapeutics has raised a total of
¥130M
in funding over 2 rounds. Their latest funding was raised on
Apr 8, 2020 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 8, 2020 | Series A | ¥130M | 1 |
Fosun International
|
— | Detail |
| Jan 1, 2018 | Angel | — | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
Neurophth Therapeutics is funded by 2 investors.
Fosun International
and Qiji Zhiguang Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Fosun International
|
Yes | Series A |
|
|
Yes | Angel |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
